Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, INTELLIA THERAPEUTICS, INC. reported revenue of $68M, up 16.9% year over year. Operating margin was -651.7% and net margin -609.9%, on a free-cash-flow margin of -585.0% with capital expenditure at 1.7% of revenue. Every figure is computed directly from NTLA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $68M | -651.7% | -609.9% |
| FY2024 | $58M | -923.1% | -896.8% |
| FY2023 | $36M | -1420.5% | -1326.5% |
| FY2022 | $52M | -879.0% | -909.8% |
| FY2021 | $33M | -810.4% | -810.5% |
How does NTLA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.